Holen Sie sich die Stockscreener-App
5.81
1.19%
-0.07
Schlusskurs vom Vortag:
$5.88
Offen:
$5.89
24-Stunden-Volumen:
1.03M
Relative Volume:
1.02
Marktkapitalisierung:
$347.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.80M
KGV:
-7.7467
EPS:
-0.75
Netto-Cashflow:
$-30.67M
1W Leistung:
+7.79%
1M Leistung:
+8.40%
6M Leistung:
-13.15%
1J Leistung:
+11.09%
1-Tages-Spanne:
$5.66
$6.05
1-Wochen-Bereich:
$5.34
$6.05
52-Wochen-Spanne:
$1.14
$7.20
Aldeyra Therapeutics Inc Stock (ALDX) Company Profile
Firmenname
Aldeyra Therapeutics Inc
Sektor
Branche
Telefon
781-761-4904
Adresse
131 HARTWELL AVENUE, LEXINGTON, MA
Vergleichen Sie ALDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALDX
Aldeyra Therapeutics Inc
|
5.81 | 326.65M | 0 | -44.80M | -30.67M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aldeyra Therapeutics Inc Stock (ALDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-04-03 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2024-04-02 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-04-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-02-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-12-16 | Eingeleitet | Berenberg | Buy |
| 2020-10-30 | Eingeleitet | Jefferies | Buy |
| 2020-10-16 | Eingeleitet | BTIG Research | Buy |
| 2020-09-22 | Eingeleitet | Alliance Global Partners | Buy |
| 2020-05-12 | Eingeleitet | Oppenheimer | Outperform |
| 2018-12-04 | Eingeleitet | Citigroup | Buy |
| 2018-09-26 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Janney | Buy |
| 2018-01-26 | Eingeleitet | Seaport Global Securities | Buy |
| 2016-09-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2016-07-01 | Eingeleitet | Stifel | Buy |
| 2015-07-01 | Eingeleitet | Canaccord Genuity | Buy |
| 2015-03-25 | Eingeleitet | Chardan Capital Markets | Buy |
| 2015-03-20 | Bestätigt | H.C. Wainwright | Buy |
| 2014-11-18 | Eingeleitet | H.C. Wainwright | Buy |
| 2014-06-19 | Eingeleitet | Aegis Capital | Buy |
Alle ansehen
Aldeyra Therapeutics Inc Aktie (ALDX) Neueste Nachrichten
Published on: 2025-08-21 07:52:25 - thegnnews.com
Don't Ignore The Insider Selling In Aldeyra Therapeutics - simplywall.st
Top Stocks to Watch: IOVA Surges on Regulatory Approval, FDA Fast Tracks Aldeyra Drug. - AInvest
Top Stocks To Watch: IOVA Soars On Regulatory Approval, FDA Fast Tracks Aldeyra's Drug - RTTNews
Aldeyra Therapeutics Gains FDA Fast Track for ADX-2191 - TipRanks
FDA grants fast track designation for Aldeyra’s eye disease drug - Investing.com
Potential Breakthrough for 1M+ Patients: Aldeyra's Eye Drug Fast-Tracked for Untreated Blindness Condition - Stock Titan
Is This the Dip to Buy in Aldeyra Therapeutics Inc.Trade Analysis Report & Real-Time Buy Signal Notifications - newsyoung.net
Aldeyra Therapeutics Insider Buys Stock Amid Regulatory Progress - AInvest
Is Aldeyra Therapeutics Inc. part of any ETF2025 Trade Ideas & Short-Term Trading Opportunity Alerts - 선데이타임즈
Does Aldeyra Therapeutics Inc. fit your quant trading modelRate Cut & Weekly Chart Analysis and Trade Guides - Newser
Is Aldeyra Therapeutics Inc. forming a bottoming baseWeekly Market Summary & Safe Entry Zone Identification - Newser
Aldeyra Therapeutics Inc. stock trendline breakdownWeekly Trend Summary & AI Powered Market Trend Analysis - Newser
Published on: 2025-08-17 02:23:20 - 선데이타임즈
Comparing Aldeyra Therapeutics Inc. in custom built stock radarsWeekly Trade Review & Long-Term Capital Growth Ideas - Newser
What high frequency data says about Aldeyra Therapeutics Inc.July 2025 PostEarnings & Pattern Based Trade Signal System - Newser
Is Aldeyra Therapeutics Inc. building a consolidation base2025 Macro Impact & Free Daily Entry Point Trade Alerts - Newser
Aldeyra Therapeutics Sees Insider Confidence with New Stock Purchase! - TipRanks
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsWeekly Profit Analysis & Reliable Volume Spike Alerts - Newser
Can Aldeyra Therapeutics Inc. expand its profit marginsJuly 2025 Sentiment & Real-Time Volume Trigger Notifications - thegnnews.com
XTX Topco Ltd Acquires New Holdings in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) - Defense World
Leerink Partnrs Issues Optimistic Forecast for ALDX Earnings - Defense World
Quantitative breakdown of Aldeyra Therapeutics Inc. recent moveJuly 2025 Price Swings & Daily Chart Pattern Signal Reports - Newser
Aldeyra Therapeutics Inc. Ranks High in Smart Money TrackerWeekly Trade Analysis & Real-Time Chart Pattern Alerts - thegnnews.com
Is Aldeyra Therapeutics Inc. stock a top performer YTDQuarterly Portfolio Review & Fast Momentum Stock Entry Tips - thegnnews.com
HC Wainwright Issues Optimistic Estimate for ALDX Earnings - Defense World
HC Wainwright Has Pessimistic Outlook of ALDX Q3 Earnings - Defense World
Aldeyra therapeutics CDO sells $113k in shares By Investing.com - Investing.com Australia
Aldeyra therapeutics CDO sells $113k in shares - Investing.com
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionAI Swing Strategy Signal Forecasting System - Newser
Buy Rating for Aldeyra Therapeutics Driven by FDA Progress and Strategic Partnership Potential - TipRanks
Aldeyra Therapeutics Inc expected to post a loss of 25 cents a shareEarnings Preview - TradingView
Aldeyra price target raised to $9 from $6 at Jones Trading on FDA acceptance - Investing.com Canada
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th A - GuruFocus
Aldeyra CEO to Share Exclusive Ophthalmology Pipeline Updates at H.C. Wainwright Conference - Stock Titan
Aldeyra Therapeutics (ALDX) Projected to Post Quarterly Earnings on Thursday - Defense World
AI Indicators Detect Buy Opportunity in Aldeyra Therapeutics Inc.Real-Time Analysis With Entry Targets In Progress - beatles.ru
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionTremendous portfolio expansion - Jammu Links News
Is Aldeyra Therapeutics Inc. a good long term investmentBuild a portfolio that outperforms the market - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock price move sharplyFree Trend-Following Techniques - Jammu Links News
How does Aldeyra Therapeutics Inc. generate profit in a changing economyPowerful profit generation - Jammu Links News
Analyzing Aldeyra Therapeutics Inc. with risk reward ratio chartsDaily Market Momentum and Pressure Analysis - Newser
Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Strongest growth potential - Jammu Links News
When is Aldeyra Therapeutics Inc. stock expected to show significant growthSky-high profits - Jammu Links News
Published on: 2025-08-02 20:17:22 - beatles.ru
Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - Jammu Links News
What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - Jammu Links News
How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”AI Powered Entry Points That Work - Jammu Links News
Exploring US High Growth Tech Stocks For July 2025 - simplywall.st
Published on: 2025-07-29 20:51:08 - metal.it
Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it
Finanzdaten der Aldeyra Therapeutics Inc-Aktie (ALDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Aldeyra Therapeutics Inc-Aktie (ALDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Machatha Stephen | Chief Development Officer |
Aug 11 '25 |
Sale |
5.15 |
22,073 |
113,713 |
221,799 |
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):